PFIZER

PFIZER

approved_indications FDA Approved Biologics and Pending Applications

Genotropin®

somatropin
NDA 20280

Inflectra®

Infliximab-dyyb
aBL 125544

Ixifi

infliximab-qbtx
BL 761072

Nivestym

filgrastim-aafi
aBL 761080

PF-06410293

adalimumab
PF-06410293 Approval Pending

Retacrit®

epoetin alfa-epbx
aBL 125545

Ruxience®

rituximab-pvvr
aBL 761103

Trazimera

trastuzumab-qyyp
aBL 761081

Zirabev

bevacizumab-bvzr
aBL 761099

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In The E.U.

Zirabev (bevacizumab) (Pfizer) (February-2019)

Biosimilars Approved In Australia

Nivestim (filgrastim) (Pfizer) (September-2010)

Biosimilars Approved In Japan

Infliximab BS 3 (infliximab) (Pfizer) (July-2018)

approved_indications Inter Partes Review Proceedings

LANTUS / LANTUS SOLOSTARIPR2019-00977
IPR2019-00978
IPR2019-00979
IPR2019-00980
IPR2019-00981
IPR2019-00982
IPR2019-00987
IPR2019-01022
IPR2019-01023
AVASTIN / ZIRABEVIPR2016-01771
IPR2018-00373
HERCEPTIN / TRAZIMERAIPR2017-00731
IPR2017-00737
IPR2017-00739
IPR2017-00804
IPR2017-00805
IPR2017-01488
IPR2017-01489
IPR2017-01726
IPR2017-01727
IPR2017-02019
IPR2017-02020
IPR2017-02063
IPR2018-00016
IPR2018-00330
IPR2018-00331
RITUXAN / RUXIENCEIPR2017-01115
IPR2017-01166
IPR2017-01167
IPR2017-01168
IPR2017-01923
IPR2017-02126
IPR2017-02127
IPR2018-00086
IPR2018-00186
IPR2018-00231
IPR2018-00285

approved_indications U.S. Patent Litigations

AVASTIN / ZIRABEV1:19-cv-00638 (D. Del.)
AVONEX / BETASERON / EXTAVIA / REBIF2:10-cv-02734 (D.N.J.)
2:10-cv-02760 (D.N.J.)
HERCEPTIN / TRAZIMERA / GENENTECH CABILLY1:17-cv-01672 (D. Del.)
NEUPOGEN / NIVESTYM1:18-cv-01064 (D. Del.)
OPDIVO / BAVENCIO1:17-cv-01029 (D. Del.)

related articles Related News Articles

Spotlight On: Biosimilar Litigations April Breyer Menon; Ha Kung Wong July 31, 2019
Spotlight On: Lantus® / Lantus® SoloSTAR® (insulin glargine recombinant) / Basaglar® (insulin glargine) April Breyer Menon; Damineh Morsali; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 31, 2019
Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) April Breyer Menon; Corinne E. Atton; Joyce L. Nadipuram; Robert S. Schwartz, Ph.D. July 31, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – June 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 9, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – May 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. June 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – April 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. May 7, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – March 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. April 5, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. March 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – January 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. February 11, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. January 9, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – November 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. December 11, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. November 12, 2018
VIDEO: Noteworthy Ongoing Biosimilar Litigation Ha Kung Wong November 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – August 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. September 6, 2018
VIDEO: FDA and FTC Cooperation to Address Anticompetitive Behavior Ha Kung Wong September 4, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. August 3, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – June 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – April 2018 April M. Breyer Menon; Corinne E. Atton; Joseph K. Yarsky; Robert S. Schwartz, Ph.D. May 3, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. January 8, 2018
VIDEO: Upcoming Patent Litigation in Biosimilars Ha Kung Wong December 12, 2017
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – November 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. December 5, 2017
VIDEO: How Important is Inter Partes Review to Biosimilars? Ha Kung Wong August 9, 2017
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 26, 2017

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha